Zoledronate suppresses VEGF‑induced capillary tube formation and inhibits expression of interferon‑induced transmembrane protein‑1 in human umbilical vein endothelial cells

International Journal of Molecular Medicine
Beom Su KimJun Lee

Abstract

Interferon‑induced transmembrane protein 1 (IFITM1) is a member of the interferon‑induced transmembrane protein family and has recently been identified as a novel protein participant in angiogenesis. Zoledronate (ZON), a nitrogen‑containing bisphosphonate, is widely used in the treatment of osteoporosis and to prevent bone metastases of certain cancer types. However, the association between ZON and IFITM1 has remained elusive. The present study investigated the effect of ZON on the expression of IFITM1 during vascular endothelial growth factor (VEGF)‑induced capillary tube formation in human umbilical vein endothelial cells. It was observed that cell proliferation and VEGF‑induced tube formation were significantly inhibited by treatment with 10 µM ZON. The expression of IFITM1 increased during VEGF‑induced tube formation. However, the VEGF‑induced increase in IFITM1 expression exhibited a dose‑ and time‑dependent decrease with ZON treatment at the mRNA and protein level. Furthermore, matrix metalloproteinase‑9 activation was markedly decreased by ZON treatment. These results suggest that induction of IFITM1 expression may be involved in the anti‑angiogenic activity of ZON.

References

Oct 12, 2000·Nature Cell Biology·G BergersD Hanahan
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jeanette WoodJonathan R Green
Sep 11, 2003·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Robert E Marx
Jan 12, 2005·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·J V BaganC Scully
Oct 26, 2005·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Robert E MarxVishtasb Broumand
Jun 8, 2007·Blood Cells, Molecules & Diseases·Zaher K OtrockAli I Shamseddine
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Jul 16, 2008·The Journal of Surgical Research·Jun YamadaHirokazu Nagawa
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroko HatanoTakashi Takata
Mar 24, 2009·Methods in Molecular Biology·M Lourdes Ponce
May 1, 2010·Journal of Vascular Research·Maria MichailidouIngunn Holen
Oct 1, 2011·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Paolo VescoviSamir Nammour
Jul 10, 2012·Diagnostic Pathology·Eugen B PetcuKlara Brinzaniuc
Sep 20, 2012·Cancer Biology & Therapy·Gabriella MissoMichele Caraglia
Mar 8, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Stephanie A PopsonChristopher C W Hughes

❮ Previous
Next ❯

Citations

Apr 30, 2020·International Journal of Molecular Sciences·Stella D'OronzoMarco Tucci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.